Zoetis (ZTS)
(Delayed Data from NYSE)
$190.03 USD
-0.96 (-0.50%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $189.97 -0.06 (-0.03%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$190.03 USD
-0.96 (-0.50%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $189.97 -0.06 (-0.03%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth F Momentum F VGM
Zacks News
Top Analyst Reports for Texas Instruments, Charter & Lowe's
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Texas Instruments (TXN), Charter Communications (CHTR) and Lowe's (LOW).
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Zoetis Surges 45.3% YTD on Strong Portfolio & New Approvals
by Zacks Equity Research
Zoetis (ZTS) surges on strong performance year to date, backed by a solid portfolio and prudent acquisitions.
Top Analyst Reports for Alibaba, Disney & Morgan Stanley
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group (BABA), Disney (DIS) and Morgan Stanley (MS).
Zacks.com featured highlights include: ResMed, Microsoft, Zoetis and Ruth???s Hospitality
by Zacks Equity Research
Zacks.com featured highlights include: ResMed, Microsoft, Zoetis and Ruth???s Hospitality
Zoetis (ZTS) Up 0.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks.com featured highlights include: ResMed, Microsoft, Zoetis and Ruth's Hospitality
by Zacks Equity Research
Zacks.com featured highlights include: ResMed, Microsoft, Zoetis and Ruth's Hospitality
4 GARP Stocks to Scoop Up for Maximum Returns
by Zacks Equity Research
If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.
JAZZ vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Zoetis (ZTS) Acquires ZNLabs to Bolster Diagnostics Portfolio
by Zacks Equity Research
Zoetis (ZTS) acquires ZNLabs and expands its reference laboratory capabilities in the United States.
Is Zoetis (ZTS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ZTS) Outperforming Other Medical Stocks This Year?
Zacks.com featured highlights include: Heico, Microsoft, Zoetis and Cadence Design System
by Zacks Equity Research
Zacks.com featured highlights include: Heico, Microsoft, Zoetis and Cadence Design System
4 GARP Stocks for a Winning Portfolio
by Zacks Equity Research
Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Sweta Killa
Style Box ETF report for FTCS
JAZZ or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
Zoetis (ZTS) Beats on Earnings in Q3, Reports In-Line Sales
by Zacks Equity Research
Zoetis (ZTS) beats earnings estimates, while sales are in line in the third quarter of 2019.
Zoetis (ZTS) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of 5.62% and 0.17%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Zoetis (ZTS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) is expected to provide pipeline updates during the third-quarter earnings call.
Zacks.com featured highlights include: Heico, Microsoft, Zoetis and Cadence
by Zacks Equity Research
Zacks.com featured highlights include: Heico, Microsoft, Zoetis and Cadence
Zoetis (ZTS) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Zoetis (ZTS) closed at $127.92, marking a +0.25% move from the previous day.
Zoetis (ZTS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 GARP Stocks to Scoop Up for Maximum Returns
by Zacks Equity Research
If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.
Is Zoetis (ZTS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ZTS) Outperforming Other Medical Stocks This Year?
5 Drug/Biotech Stocks Likely to Surpass on Earnings in Q3
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the third quarter.
JAZZ vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
JAZZ vs. ZTS: Which Stock Is the Better Value Option?